Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Mikhail N KosiborodMark C PetrieBarry A BorlaugJaved ButlerMelanie J DaviesG Kees HovinghDalane W KitzmanDaniél V MøllerMarianne B TreppendahlSubodh VermaThomas J JensenKaroline LiisbergMarie L LindegaardWalter AbhayaratnaFozia Z AhmedTuvia Ben-GalVijay ChopraJustin A EzekowitzMichael FuHiroshi ItoMałgorzata LelonekVojtěch MelenovskýBela MerkelyJulio NunezEduardo Roque PernaMorten SchouMichele SenniKavita SharmaPeter van der MeerDirk Von LewinskiDennis WolfSanjiv J Shahnull nullPublished in: The New England journal of medicine (2024)
Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).